2,050 reports of this reaction
2.4% of all FULVESTRANT reports
#9 most reported adverse reaction
METASTASES TO BONE is the #9 most commonly reported adverse reaction for FULVESTRANT, manufactured by AstraZeneca Pharmaceuticals LP. There are 2,050 FDA adverse event reports linking FULVESTRANT to METASTASES TO BONE. This represents approximately 2.4% of all 86,552 adverse event reports for this drug.
Patients taking FULVESTRANT who experience metastases to bone should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
METASTASES TO BONE is a less commonly reported adverse event for FULVESTRANT, but still significant enough to appear in the safety profile.
In addition to metastases to bone, the following adverse reactions have been reported for FULVESTRANT:
The following drugs have also been linked to metastases to bone in FDA adverse event reports:
METASTASES TO BONE has been reported as an adverse event in 2,050 FDA reports for FULVESTRANT. This does not prove causation, but indicates an association observed in post-market surveillance data.
METASTASES TO BONE accounts for approximately 2.4% of all adverse event reports for FULVESTRANT, making it a notable side effect.
If you experience metastases to bone while taking FULVESTRANT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.